Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 386

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 386
---
,964 | ) |
| Cash, beginning of the period                                                        |     |                                      |     16,868 |   |     |                                      |    204,464 |   |
| Cash, end of the period                                                              |     | $                                    |        126 |   |     | $                                    |      1,500 |   |
| Supplemental disclosure of noncash investing and financing activities                |     |                                      |            |   |     |                                      |            |   |
| Increase in investment held in Trust Account through issuance of promissory note     |     | $                                    |     47,815 |   |     | $                                    |    300,000 |   |
| Remeasurement adjustment on class A ordinary shares subject to possible redemption   |     | $                                    |    144,866 |   |     | $                                    |  1,594,042 |   |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-38

Denali Capital Acquisition Corp. Notes to Unaudited Consolidated Financial Statements NOTE 1 - ORGANIZATION AND BUSINESS OPERATION Denali Capital Acquisition Corp. (the “Company” or “Denali”) is a newly organized blank check company incorporated in the Cayman Islands on January 5, 2022. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses (a “Business Combination”). As of June 30, 2025, the Company had not commenced any operations. All activity for the period from January 5, 2022 (inception) through June 30, 2025, relates to the Company’s organizational activities, those necessary to prepare for and complete the initial public offering (“IPO”), identifying a target company for a business combination, and activities in connection with an initial business combination, including with respect to our proposed business combination with Semnur Pharmaceuticals, Inc (“Semnur”). The Company does not expect to generate any operating revenues until after the completion of an initial Business Combination. The Company is generating non-operating income in the form of income from the investment of proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the “Sponsor”). Financing The registration statement for the Company’s IPO became effective on April